No Data Yet
Major insiders, including Roivant Sciences and GSK, invested over $550 million into biotech firms Immunovant, Kymera Therapeutics, and Wave Life Sciences following their recent secondary share offerings.
A valuation update for Kimberly-Clark reveals a minor reduction in its fair value estimate, attributed to execution risks from the planned Kenvue acquisition. This caution persists even as analysts have increased revenue growth projections, signaling market uncertainty.